Taming the Double-Edged Sword – A New Chapter in ALK4/5 Targeting

1. Biological Basis of ALK4 and ALK5

ALK4 (Activin Receptor-Like Kinase 4, also known as ACVR1B) and ALK5 (TGF-β Type I Receptor, TβRI) are core type I receptor kinases in the TGF-β superfamily signaling pathway. The TGF-β signaling pathway is crucial for regulating cell proliferation, differentiation, apoptosis, and tissue fibrosis, and its abnormal activation is closely associated with tumors, fibrotic diseases, and developmental disorders.

ALK5 is the primary type I receptor for TGF-β1/2/3. Upon binding to TGF-β ligands, the glycine-serine-rich domain in the juxtamembrane region of ALK5 becomes phosphorylated, subsequently phosphorylating downstream Smad2/3 proteins. Phosphorylated Smad2/3 forms a complex with Smad4, translocates into the nucleus, and regulates target gene transcription.

ALK4 primarily mediates Activin and Nodal signaling, playing important roles in embryonic development, reproductive regulation, and tumor suppression. Studies have shown that ALK4 mediates the antiproliferative effects of Activin in pituitary tumor cells, and the loss of ALK4 expression eliminates this growth-inhibitory effect.

2. Classification and Representative Compounds of ALK4/ALK5 Inhibitors

SB-431542 is the most extensively studied selective inhibitor of ALK4/5/7, with minimal impact on BMP pathway-related ALK1/2/3/6 and no interference with JNK, ERK, or p38 MAPK pathways. A-83-01 exhibits higher inhibitory activity, with an IC₅₀ of 12 nM for ALK5 and 45 nM for ALK4, and is widely used to maintain pluripotency in rat iPSCs and induce neural fate conversion.

To overcome side effects such as cardiotoxicity associated with systemic ALK5 inhibition, next-generation drug development focuses on tissue-restricted delivery:

AGMB-129 (Ontunisertib): An oral, intestine-restricted ALK5 inhibitor for treating fibrostenotic Crohn's disease (FSCD). In November 2025, Agomab announced positive data from the STENOVA Phase IIa trial, and the drug has entered Phase IIb clinical development.
AGMB-447: An inhaled, lung-restricted ALK5 small-molecule inhibitor for treating idiopathic pulmonary fibrosis (IPF). In January 2026, Agomab reported positive interim results from a Phase I study in healthy subjects and received FDA orphan drug designation.

This "restricted distribution" strategy aims to confine drug exposure to target organs, thereby avoiding the risk of heart valve toxicity associated with traditional ALK5 inhibitors.

3. Clinical Development Progress and Challenges

As of 2025, several ALK5 inhibitors have entered clinical studies. In addition to the tissue-restricted drugs mentioned above, representative clinical candidates include:

LY2157299 (Galunisertib): An ALK5 inhibitor developed by Eli Lilly, which has completed clinical trials for glioma and pancreatic tumors and is undergoing Phase II studies in hepatocellular carcinoma and glioblastoma, demonstrating manageable toxicity profiles and antitumor activity.
EW-7197 (Vactosertib): A drug for Phase I clinical trials in advanced solid tumors, showing therapeutic potential in 3D chip models of renal fibrosis.
Zelasudil (RXC007): A drug developed by Redx Pharma, which faced a partial FDA clinical hold for its Phase IIa trial in IPF but was lifted in January 2026.

The greatest obstacle to the clinical translation of ALK5 inhibitors is heart valve lesions. Preclinical studies have found that small-molecule ALK5 inhibitors can induce heart valve damage, severely limiting the application of systemic administration strategies. Therefore, tissue-restricted delivery (e.g., inhalation, intestinal targeting) and the design of highly selective inhibitors have become core directions in current research.

4. Therapeutic Applications

1. Antifibrotic Therapy
ALK5 is a core driver of tissue fibrosis. In idiopathic pulmonary fibrosis (IPF), ALK5 inhibitors have become an important research direction, alongside drugs such as BMS-986278 and Deupirfenidone, forming a significant part of the IPF clinical pipeline. In renal fibrosis, ALK5 inhibitors exert antifibrotic effects by reducing type I procollagen and PAI-1 expression.

2. Antitumor Therapy
TGF-β/ALK5 signaling has a "double-edged sword" effect in tumors: inhibiting tumor growth in early stages but promoting epithelial-mesenchymal transition (EMT), immune escape, and metastasis in advanced stages. ALK5 inhibitors can block TGF-β-induced EMT, inhibiting tumor cell migration and invasion. In hepatocellular carcinoma, LY2157299 can block CTGF production and reduce stromal responses.

3. Regenerative Medicine and Stem Cell Differentiation
ALK4/5 inhibitors are indispensable in stem cell engineering. SB-431542 combined with the MEK inhibitor PD0325901 can significantly improve somatic cell reprogramming efficiency; A-83-01 can maintain long-term homogeneous self-renewal in rat iPSCs and rapidly induce neuronal fate conversion in mouse embryonic stem cells.

5. Future Perspectives

As core signaling nodes in the TGF-β superfamily, ALK4 and ALK5 drug development is undergoing a paradigm shift from "pan-inhibition" to "precision targeting." Recent reviews have systematically summarized the structure-activity relationships (SAR) and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of ALK5 inhibitors, providing important references for rational drug design.

With next-generation tissue-restricted ALK5 inhibitors from companies like Agomab entering late-stage clinical trials, the ALK4/ALK5 targets are expected to achieve breakthroughs in fibrotic diseases and tumor therapy.

Related Product Recommendations

© Cutting-Edge Target Insights · Summary of Latest Research on ALK4/ALK5 Signaling Pathway | Data updated to 2026